Core Viewpoint - The company announced the issuance of 5.8 million convertible bonds, raising a total of 580 million yuan, with a net amount of 574 million yuan, all of which has been received [1] Group 1: Fundraising Details - The company will issue 5.8 million convertible bonds on December 11, 2025, raising 580 million yuan [1] - The net proceeds from the bond issuance amount to 574 million yuan [1] Group 2: Investment Project - The raised funds will be primarily allocated to the "Thailand Production Base Construction Project," which has a total investment of 596 million yuan [1] - To enhance fund utilization efficiency, the company plans to use letters of credit and foreign exchange for payments, subsequently replacing them with the raised funds [1] Group 3: Board Approval - The company's board of directors approved the fundraising and investment plan on December 23, 2025, with no objections from the sponsoring institution [1]

Group 1 - The company approved the use of raised funds to replace self-raised funds previously invested in projects and to cover issuance costs, totaling CNY 173,451,008.52 [2][5][34] - The company issued 5.8 million convertible bonds at CNY 100 each, raising a total of CNY 58,000 million, with a net amount received of CNY 57,540 million after deducting fees [11][20][42] - The funds raised were fully received by December 17, 2025, and were verified by an accounting firm [11][20][42] Group 2 - The total investment amount for the projects funded by the raised capital is CNY 59,604.21 million, with all raised funds allocated to these projects [4][22] - The company can use self-raised funds for project investments before the raised funds are available, and these can be replaced once the funds are received [4][5] - The company has established a special account for the raised funds and signed a tripartite supervision agreement with the banks and the sponsor [21][43] Group 3 - The company plans to use up to CNY 45,000 million of temporarily idle raised funds for cash management, ensuring it does not affect project construction [17][25][29] - The cash management products will include low-risk, liquid, and principal-protected options such as time deposits and structured deposits [17][24][29] - The board approved the cash management plan on December 23, 2025, allowing for rolling use of funds within a 12-month period [19][29][30] Group 4 - The company will use self-raised funds, foreign exchange, and letters of credit to pay for project costs and will replace these with raised funds later [42][46][48] - This approach aims to enhance operational efficiency and reduce financial costs while ensuring compliance with regulations [46][48] - The board approved this method on December 23, 2025, confirming it aligns with legal and regulatory requirements [47][48]

交易信息汇总 资金流向 12月23日主力资金净流出370.98万元，占总成交额5.12%；游资资金净流出261.31万元，占总成交额 3.61%；散户资金净流入632.29万元，占总成交额8.73%。 公司公告汇总 截至2025年12月23日收盘，澳弘电子(605058)报收于29.97元，下跌1.02%，换手率1.7%，成交量2.42万 手，成交额7245.01万元。 当日关注点 澳弘电子第三届董事会第十次会议决议公告 常州澳弘电子股份有限公司于2025年12月23日召开第三届董事会第十次会议，审议通过多项议案。同意 使用募集资金173,451,008.52元置换预先投入募投项目及已支付发行费用的自筹资金。为提高资金使用 效率，公司将在募投项目实施期间使用自有资金、外汇、信用证等方式支付相关款项，并以募集资金等 额置换。同时，同意公司及子公司使用不超过45,000万元的闲置募集资金进行现金管理，期限为12个 月，资金可循环使用，投资品种为安全性高、流动性好的保本型产品。 澳弘电子关于使用闲置募集资金进行现金管理的公告 常州澳弘电子股份有限公司于2025年12月23日召开第三届董事会第十次会议，审议通过使用不 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 常州澳弘电子股份有限公司 关于使用自有资金、外汇及信用证等方式支付 募投项目款项并以募集资金等额置换的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 常州澳弘电子股份有限公司(以下简称"公司"或"澳弘电子")于2025年12月23日召开了第三届董事会第十 次会议，审议通过了《关于使用自有资金、外汇及信用证等方式支付募投项目所需资金并以募集资金等 额置换的议案》，同意公司及子公司在募集资金投资项目实施期间,根据实际需要并经相关审批后使用 信用证、外汇、保函、自有资金等方式支付募投项目所需资金并以募集资金等额置换。保荐机构国金证 券股份有限公司(以下简称"保荐机构")对本事项出具了无异议的核查意见。现将具体情况公告如下： 一、募集资金基本情况 四、使用信用证、外汇、保函、自有资金等方式支付募投项目款项并以募集资金等额置换的流程 为提高公司募集资金使用效率、保障募投项目正常推进，公司及子公司计划在募投项目实施期间，根据 实际情况并经内部相关审批后使用信用证、 ...

（文章来源：证券日报） 证券日报网讯 12月23日，澳弘电子发布公告称，公司第三届董事会第十次会议审议通过《关于使用募 集资金置换预先投入的自筹资金的议案》等多项议案。 ...

Group 1 - Shareholder of Okoyi plans to reduce holdings by up to 1.89% of the company's shares, amounting to a maximum of 3 million shares due to personal funding needs [1] - Tianchuang Fashion is planning a change in control, leading to continued suspension of its stock trading, expected to last no more than 3 trading days [2] - China Electric Power Construction Company reported a new contract amount of 10,317.55 billion yuan for the first 11 months of 2025, a year-on-year decrease of 1.65% [3] Group 2 - Pilin Bio's wholly-owned subsidiary received approval for a clinical trial of a drug, indicating progress in its product development [4] - Yihong Medical obtained two medical device registration certificates for diagnostic kits, enhancing its product portfolio [5] - Aohong Electronics plans to use up to 450 million yuan of idle fundraising for cash management, targeting safe and liquid financial products [6] Group 3 - China Electric Power Construction signed a contract worth approximately 6.626 billion yuan for a natural gas booster station project in Turkey, with a construction period of about 55 months [7] - Baosheng Co. won a bid for a power cable project in Singapore, valued at around 1.2 billion yuan, marking the largest overseas order in its history [8] - *ST Xinyan's stock will resume trading on December 24, 2025, following a capital increase plan that will raise its total share capital to 3.29 billion shares [9] Group 4 - Ningbo Construction's subsidiary signed a construction contract worth 428 million yuan for an engineering project with a duration of 990 days [11] - Lianhuan Pharmaceutical's subsidiary received approval for a drug that passed the consistency evaluation for generic drugs, enhancing its market competitiveness [12] - Zhongjie Automotive received a project designation for a new electric air conditioning compressor, with expected sales of approximately 29.86 million USD over its lifecycle [13] Group 5 - Biopharmaceuticals' major shareholder plans to increase holdings by 50 million to 100 million yuan, indicating confidence in the company's future [14] - Haizheng Pharmaceutical's subsidiary received approval for a veterinary drug product, expanding its product offerings in the animal health sector [15] - *ST Songfa's subsidiary signed contracts for the construction of 8 vessels, with a total contract value between 200 million to 400 million USD [16] Group 6 - Shandong Pharmaceutical Glass announced the resignation of its chairman due to age reasons, indicating a potential leadership transition [17] - Xinno Wei's subsidiary received approval for a clinical trial of a monoclonal antibody drug, indicating advancements in its drug development pipeline [18] - Ningbo Huaxiang's subsidiary secured an order for robot joints, expected to positively impact future business performance [19][20] Group 7 - China Resources Double Crane's subsidiary received approval for a clinical trial of a drug aimed at treating a genetic eye disease, reflecting ongoing R&D efforts [21] - Huaxin Technology's shareholders set a transfer price of 56.69 yuan per share for a block of shares, indicating active shareholder engagement [22] - Xinhua Net announced the resignation of its president due to job relocation, suggesting potential changes in management [23] Group 8 - Taiji Group plans to transfer a 40% stake in a subsidiary to focus on its core pharmaceutical business, enhancing operational efficiency [24] - Huaxin Construction's shareholder plans to increase holdings by 200 million to 400 million yuan, reflecting confidence in the company's prospects [25] - Dongjie Intelligent is planning to issue shares and cash for asset acquisition, with stock trading suspended until further notice [26] Group 9 - Wanrun New Energy was designated as a delivery warehouse for lithium carbonate futures, indicating its strategic position in the market [27] - Prolo Pharmaceutical's subsidiary received a drug registration certificate for an influenza treatment, expanding its product range [28] - Saiwu Technology invested 5 million yuan in a private equity fund focused on smart vehicles and energy innovation, indicating strategic investment in growth sectors [29] Group 10 - Bohui Innovation's subsidiary received approval for a clinical trial of an immunoglobulin drug, indicating progress in its product development [30] - Bohui Innovation's subsidiary also received a drug registration certificate for a coagulation factor product, enhancing its therapeutic offerings [31] - Hanghua Co. plans to allocate 146 million yuan of surplus fundraising for a new green printing materials project, reflecting a commitment to sustainability [32] Group 11 - Nova Star Cloud obtained a loan commitment letter from a bank for a share repurchase plan, indicating financial support for its capital management strategy [33] - Jimin Health established a joint venture for technology innovation, indicating a strategic move to enhance its technological capabilities [34] - Huili Pharmaceutical received a drug registration certificate for a medication used in treating digestive ulcers, expanding its product portfolio [35]

Group 1 - The company, Aohong Electronics, announced that its third board meeting will be held on December 23, 2025, to discuss the use of idle fundraising for cash management [1] - For the year 2024, Aohong Electronics' revenue composition is 92.13% from the printed circuit board industry and 7.87% from other businesses [1] Group 2 - The current market capitalization of Aohong Electronics is 4.3 billion yuan [2]

格隆汇12月23日丨澳弘电子(605058.SH)公布，公司计划使用不超过人民币45,000.00万元(含本数)的暂时 闲置募集资金进行现金管理。本次审议的现金管理有效期为自本次董事会审议通过之日起12个月在前述 额度和期限内，资金可循环滚动使用，任一时点投资余额不得超过前述投资额度，产品期限不得长于内 部决策授权使用期限，且不得长于12个月。 ...

证券代码：605058 证券简称：澳弘电子 公告编号：2025-063 常州澳弘电子股份有限公司 关于使用募集资金置换预先投入募投项目及已支付发行费用 的自筹资金公告 本公司《常州澳弘电子股份有限公司向不特定对象发行可转换公司债券证券 募集说明书》披露的募集资金投资项目及募集资金使用计划如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司使用募集资金置换预先投入募集资金投资项目及已支付发行费用的 自筹资金的金额，符合募集资金到账后 6 个月内进行置换的规定。 常州澳弘电子股份有限公司(以下简称"公司"或"澳弘电子")于 2025 年 12 月 23 日召开第三届董事会第十次会议,审议通过了《关于使用募集资金置换 预先投入的自筹资金的议案》，同意公司使用募集资金置换预先投入募投项目自 筹资金 172,222,706.62 元，使用募集资金 1,228,301.90 元置换预先支付发行费 用的自筹资金，合计 173,451,008.52 元。现将相关事项公告如下： 一、募集资金基本情况 根据中国证券监督管理 ...

证券代码：605058 证券简称：澳弘电子 公告编号：2025-062 常州澳弘电子股份有限公司 关于签订募集资金专户存储监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意常州澳弘电子股份有限公司向不特 定对象发行可转换公司债券注册的批复》(证监许可(2025)2543 号)，常州澳弘 电子股份有限公司(以下简称"公司"或"澳弘电子")于 2025 年 12 月 11 日公 开发行了 580 万张可转换公司债券，发行价格为每张 100 元，募集资金总额为人 民币 58,000.00 万元，扣除承销费用及保荐费用合计 460.00 万元(不含增值税)， 实际收到募集资金 57,540.00 万元。本次向不特定对象发行可转换公司债券发行 费 用 5,902,830.19 元 ( 不 含 增 值 税 ) ， 实 际 募 集 资 金 净 额 为 人 民 币 574,097,169.81 元。前述募集资金已于 2025 年 12 月 17 日全部到账，容诚会计 师事 ...